Real‐World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis

R. Curtis, Jeffrey; Lynn Palmer, J.; Reed, George; D. Greenberg, Jeffrey; A. Pappas, Dimitrios; R. Harrold, Leslie; M. Kremer, Joel

doi:10.1002/acr.24253

Public

Real‐World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis

Published in Arthritis Care & Research • May 6, 2020

Authors:

Jeffrey R. Curtis

J. Lynn Palmer

George Reed

Abstract

OBJECTIVE: Though randomized controlled trials have demonstrated relatively comparable clinical outcomes with triple therapy (methotrexate [MTX], sulfasalazine [SSZ], and hydroxychloroquine [HCQ]) compared to combination therapy (tumor necrosis factor inhibitor [TNFi] and MTX), real-world experience...

Subject

Medicine

Hydroxychloroquine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!